

### Disclaimer

This presentation contains forward-looking statements about Linde AG ("Linde") and their respective subsidiaries and businesses. These include, without limitation, those concerning the strategy of an integrated group, future growth potential of markets and products, profitability in specific areas, the future product portfolio, development of and competition in economies and markets of the Group.

These forward looking statements involve known and unknown risks, uncertainties and other factors, many of which are outside of Linde's control, are difficult to predict and may cause actual results to differ significantly from any future results expressed or implied in the forward-looking statements on this presentation.

While Linde believes that the assumptions made and the expectations reflected on this presentation are reasonable, no assurance can be given that such assumptions or expectations will prove to have been correct and no guarantee of whatsoever nature is assumed in this respect. The uncertainties include, inter alia, the risk of a change in general economic conditions and government and regulatory actions. These known, unknown and uncertain factors are not exhaustive, and other factors, whether known, unknown or unpredictable, could cause the Group's actual results or ratings to differ materially from those assumed hereinafter. Linde undertakes no obligation to update or revise the forward-looking statements on this presentation whether as a result of new information, future events or otherwise.

### Agenda



### Prof. Dr Wolfgang Reitzle

#### Part 1

- 1. Performance 2013
- 2. Strategic Focus:
  - HPO
  - Gases & Engineering
  - Mega-trends
- 3. Outlook

#### Part 2

- 1. Operational Performance & Capex
- 2. Financial Performance & Dividend
- 3. Investment Highlights

### Appendix

Georg Denoke

## **Performance 2013 | Highlights** Well positioned.



[€]	2012	2013	yoy [%]
Revenue [m]	15,833	16,655	+5.2%
Operating Profit* [m]	3,686	3,966	+7.6%
Operating Margin [%]	23.3	23.8	+ 50bp
Operating Cash Flow [m]	2,664	3,144	+18.0%
EPS reported	6.93	7.10	+2.5%

- Solid growth realised in an unfavourable macro economic environment and despite significant currency headwinds in the second half of the reporting year
- Growth supported by acquisitions in Healthcare and strong Engineering performance
- Strong operating cash flow

Data in this presentation prior to 2012 is not adjusted for the application of IFRS 10, IFRS 11 and IAS 19

\* For this presentation please see definition for operating profit, ROCE reported/adjusted on page 43

# **Group | Revenue and operating profit by division** Increase of Group and Gases margin





#### Gases

Growth supported by Lincare acquisition and ramp-up of Tonnage plants;

Slight acceleration of comp. growth in Q4 against Q3

#### Engineering

Project progress triggered strong growth



#### Gases

Margin improvement in all operating segments contributed to strong operating profit development


#### Engineering

Margin remained on a world-leading high level

### **Strategic Focus | High Performance Organisation** HPO: Gross cost reduced by € 1 billion



- HPO 2013:
   Well on track with an overall reduction of the gross cost basis by € 220 million
- HPO 2009-2013:
- Gross cost reduced by € 1 billion since the start of HPO
- HPO 2013 to 2016:
   € 750 900 million of gross cost savings targeted



### **Strategic Focus | Gases & Engineering** Realising opportunities through a unique setup




	Engineering	Synergy Driver	Benefits for Gases	
		Highly competitive cost and energy efficient plants	Optimised cost of assets for production	
	Technology leadership ୪ execution expertise	Innovation and continuous improvement of products	Strengthening future competitive position	
		Long track-record of executing large-scale projects	Enables to win large-scale projects esp. in Energy & Environment sector	
		Strong customer relationships	Early awareness of potential new outsourcing projects	
Custon	Customer access	strong customer relationships	Opportunity for decaptivation	
		Insights into customer processes across industries and regions	Winning customers through gases applications	
	Opportunity	Balancing between plant sales and outsourcing model	Realising sales within the Group while optimising portfolio (capex and project risk)	

### **Strategic Focus | Gases** Creating lasting customer benefit through applications



#### Adding value by

- Continuous development of new applications and further enhancement of existing applications
- Provision of expertise in the form of new solutions and services
- Offering customised products and services




### Strategic Focus | Mega-trends






# Mega-trend | Growth Markets Strong investments in future growth

THE LINDE GROUP



### Mega-trend | Growth Markets Growth Market leader






Source: Linde data May 2013, figures for industrial gases and respiratory healthcare, excl. Japan, equipment and major impacts out of future mega-projects in energy/environment

## Mega-trend | Energy/Environment Importance of new technologies & gases applications






(please find assumptions for estimates on page 40)

### Mega-trend | Energy/Environment Opportunities resulting from US shale gas





\*Source: U.S. Energy Information Administration, April 2011, in trill. cubic feet

## **Mega-trend | Healthcare** Respiratory market growth CAGR of 4-5% till 2020



#### Market drivers

- Growing and ageing population
- High portion of untreated patients
- Increasing chronic diseases
   like sleep apnoea and COPD
- Increasing wealth in Growth Markets
- Increasing demand for offerings that reduce healthcare costs overall
- Trend towards market consolidation



### Linde's business profile

- Constant growth, independent of industrial production
- Global presence (60 countries)
- 1.4 million homecare patients lead to economies of scale
- Supply of ~20,000 hospitals
- Lincare's market share further increased to 30%
- Know-how transfer between markets (e.g. distribution network, cost leadership)
- Strong relationship to payors
- Development of cost-effective and reliable products and services




### Demand & development

- New and innovative pharmaceutical and medical gases
- Cooperation with patients, doctors and payors
- Comprehensive service offerings at home and in hospitals
- High quality and optimum care for patients at home and in hospitals
- Trend towards homecare relieves healthcare budgets



## **Strategic Focus | Healthcare** Serving the patient in all different environments





### **Outlook\*** Well positioned.



Short-term outlook	2014
Revenue	Solid increase vs. 2013 adjusted for currency effects
Operating Profit	Moderate increase vs. 2013 adjusted for currency effects
Gases Division	Moderate revenue and operating profit increase vs. 2013 adjusted for currency effects
Engineering Division	Solid revenue increase vs. 2013 & operating margin of around 10%

Medium-term outlook	2016	Potential currency impact**
Operating Profit	At least 5 billion Euro	Around - € 400 m
ROCE reported	Around 13%	Potentially impacted
HPO 4yrs programme	750-900 million Euro	

\*please see assumptions and indications on page 104f of the financial report 2013

\*\*against exchange rates at the target setting date (2012)

### Agenda



#### Part 1

- 1. Performance 2013
- 2. Strategic Focus:
  - НРО
  - Gases & Engineering
  - Mega-trends
- 3. Outlook

#### Part 2

- 1. Operational Performance & Capex
- 2. Financial Performance & Dividend
- 3. Investment Highlights

### Appendix


Prof. Dr Wolfgang Reitzle


#### Georg Denoke

### **Operational Performance | Financial key indicators** Strong operating cash flow development



- **Operating cash flow:** Strong increase by 18%
- Net debt: Deleveraged from  $\in$  8.5 bn to  $\in$  8.2 bn
- **Dividend:** Strong dividend development (+11.1%) from € 2.70 to € 3.00







<sup>\*</sup>excluding effect of € 70 m of impairments in 2013

### **Group | Currency impact** Impact on revenue and operating profit in 2013








## **Gases Division | Revenue bridge** Price/volume increase of 3.3%





\*including € 112 m changes in consolidation from bolt-on acquisitions (European Healthcare acquisitions and others) and not adjusting for the reversal of the purchase of ASUs

# Gases Division | Revenue by product areas Stable growth in a challenging macro-environment





\*excluding currency, natural gas price effect and Lincare

\*\* Competitive Bidding 2 in the US is effective since 1 July 2013

# Gases Division | Revenue by operating segment Underlying growth in all segments





- Growth driven by plant start & ramp-ups in Tonnage and Healthcare acquisitions
- Slow development in some Eastern European countries
- Negative impacts from exchange rates in particular from South Africa




- 8.0% comparable growth in Asia, adjusted for the reversal of the purchase of ASUs in China
- Highest growth rates in Tonnage and Bulk
- South Pacific restrained by economic development and currency



- Lincare acquisition strongly supported development in Healthcare
- Accelerated Bulk growth mainly driven by pricing
- Weak Brazilian economy and headwinds from currencies

# Gases Division | Operating profit by operating segment Margin improvement in all segments





### Margin development

- Further improvement of margin in all regional business units in EMEA
- Asia/Pacific positive margin development despite weak economy in South Pacific
- Americas margin supported by solid Lincare performance

# Gases Division | Market opportunities & project pipeline Project pipeline execution on track





- Level of market opportunities remained relatively stable on a high level
- Increased opportunities in Energy/Environment with actively converting some coal-to-x opportunities into Engineering sales




- Increase of 2016 projects by € 50 m
- Around 70% of investments in 2014-2016 are allocated to Growth Markets
- Due to larger average project size, average project execution time increased

Status: 31/12/2013 for projects > € 10 m

#### Amount of committed projects by on-stream date


### Gases Division | Capex Development capex/sales ratio 2009-2013





# **Engineering Division | Key figures** Record operating profit and order intake







- Synergetic set-up of Gases and Engineering successfully utilised to capture market opportunities resulting in strong internal and external order intake
- Order intake: ~ 70% of order intake from Asia/Pacific and Americas and ~60% in the product lines air separation plants and hydrogen/syngas-plants
- Strong order intake for coal gasification and shale gas related projects

# **Financial Performance | Solid financial position** Positive cash flow development supported debt reduction





- Positive cash flow development supported net debt decrease to € 8.2 bn
- Lincare acquisition credit facility entirely refinanced with capital market debt
- € 400 m of subordinated bonds redeemed in July 2013



Net debt/EBITDA ratio improved to 2.1x


– Տ&P։

Rating upgrade (revised corporate rating criteria) to A+/A-1 with stable outlook (12 Dec 2013)

Moody's:
 A3/P-2 with stable outlook (20 Jan 2014)

### **Financial Performance | Dividends** Proposed dividend increase by 11.1% to € 3.00






2007 comparable change: prior year figures including twelve months of BOC

# Well positioned Investment Highlights

- LeadIng Gas & Engineering company
- High quality portfolio
- Resilient business model
- Sustainable profitable growth





### Agenda



#### Part 1

- 1. Performance 2013
- 2. Strategic Focus:
  - НРО
  - Gases & Engineering
  - Mega-trends
- 3. Outlook

### Part 2

- 1. Operational Performance & Capex
- 2. Financial Performance & Dividend
- 3. Investment Highlights


### Appendix

Prof. Dr Wolfgang Reitzle

#### **Georg Denoke**

# Group | Financial position Conservative financing strategy






#### Maturity profile remains very long-dated

- Approx. 90% of total financial debt is due beyond 2014
- Approx. 50% of total financial debt has a longer maturity than 5 years

### Financial debt by instrument



#### **Excellent access to capital markets**

- Long-term refinancing across markets and currencies
- 2013: Issue of € 650 m 10y senior notes with a coupon of 2.00%
- 2013: Placement of USD 500 m 5y senior notes with a coupon of 1.50%

# **Group | Financial position** Liquidity position remains strong

Cash & cash equivalents



€ 2.5 bn committed revolving credit facility	Central liquidity position		
<ul> <li>2013: Early refinancing with 33 domestic and international banks</li> <li>Maturing in 2018, extendable by up to 2 years</li> <li>No financial covenants</li> <li>Fully undrawn</li> </ul>	<ul> <li>Strong liquidity profile remains centerpiece in financial strategy</li> <li>Supported by continuous efforts to upstream cash</li> <li>Very conservative investment guidelines</li> </ul>		
[€m]	2,687		
	2,500		
1,178			
	170		

**Current securities** 

Revolving credit facility

Short-term financial debt

Status: 31/12/2013


Liquidity reserve

### **Group | Pensions** Key figures FY 2013




Net obligation

Pension pla	n assets	portfolio	structure
-------------	----------	-----------	-----------



\* Figure does not include effects from asset ceiling and provisions for similar obligations



## **Group | FY 2013** Key P&L items



[€m]	FY 2012	FY 2013	Δ in %
Revenue	15,833	16,655	5.2
Operating profit	3,686	3,966	7.6
Operating margin	23.3%	23.8%	+ 50 bp
PPA depreciation for BOC	-260	-225	13.5
Depreciation & amortisation (excl. PPA BOC)	-1,371	-1,570	-14.5
EBIT	2,055	2,171	5.6
Financial result	-321	-377	-17.4
Taxes	-393	-364	7.4
Profit for the year – attributable to Linde AG shareholders	1,232	1,317	6.9
EPS reported [€]	6.93	7.10	2.5

### **Group | FY 2013** Cash flow statement



[€m]	Q1 13	Q2 13	Q3 13	Q4 13	2013	2012
Operating profit	953	1,013	1,030	970	3,966	3,686
Change in working capital	-259	-28	119	192	24	-294
Other changes	-172	-315	-183	-176	-846	-728
Operating cash flow	522	670	966	986	3,144	2,664
Investments in tangibles/intangibles	-493	-507	-525	-637	-2,162	-1,863
Acquisitions	-61	-23	-55	-4	-143	-2,997
Other (incl. financial investments)	16	28	51	35	130	125
Investment cash flow	-538*	-502*	-529*	-606*	-2,175*	-4,735*
Free cash flow before financing	-16	168	437	380	969	-2,071
Interests and swaps, dividends	-79	-648	-133	-82	-942	-899
Capital increase	0	0	0	0	0	1,391
Other changes	-5	42	2	-12	27	-451
Net debt increase (+)/decrease (-)	100	438	-306	-286	-54	2,030

\*Excluding investments in/disposals of securities; 2013: +€ 651m (Q1: +€ 279m / Q2: -€ 48m, Q3 :+€ 269m, Q4 :+€ 151m); 2012: +€ 850m

### Group | Q4 2013 Key P&L items



[€m]	Q4 2012	Q4 2013	Δ in %
Revenue	4,364	4,187	-4.1
Operating profit	1,006	970	-3.6
Operating margin	23.1%	23.2%	+10 bp
PPA depreciation for BOC	-63	-55	12.7
Depreciation & amortisation (excl. PPA BOC)	-403	-388	3.7
EBIT	540	527	-2.4
Financial result	-70	-89	-27.1
Taxes	-100	-86	14.0
Profit for the year – attributable to Linde AG shareholders	339	320	-5.6
EPS reported [€]	1.84	1.72	-6.5


### Gases Division | Quarterly data Operating segments



EMEA [€m]	Q1 2012	Q1 2013	Q2 2012	Q2 2013	Q3 2012	Q3 2013	Q4 2012	Q4 2013
Revenue	1,460	1,497	1,514	1,549	1,544	1,523	1,543	1,521
Operating profit	419	430	425	446	436	438	442	445
Operating margin	28.7%	28.7%	28.1%	28.8%	28.2%	28.8%	28.6%	29.3%
Asia/Pacific [€m]	Q1 2012	Q1 2013	Q2 2012	Q2 2013	Q3 2012	Q3 2013	Q4 2012	Q4 2013
Revenue	896	926	959	971	1,029	946	976	924
Operating profit	234	240	250	257	259	250	253	258
Operating margin	26.1%	25.9%	26.1%	26.5%	25.2%	26.4%	25.9%	27.9%
Americas [€m]	Q1 2012	Q1 2013	Q2 2012	Q2 2013	Q3 2012	Q3 2013	Q4 2012	Q4 2013
Revenue	672	1,054	680	1,083	947	1,053	1,095	1,041
Operating profit	170	272	181	270	233	310	264	230
Operating margin	25.3%	25.8%	26.6%	24.9%	24.6%	29.4%	24.1%	22.1%


### **Gases Division | Currency impact** Negative impact on revenue of 4.5%





## Gases Division | Split of capex High level of investment in future growth





- In EMEA a major part of the capex increase is dedicated to Tonnage
- In Asia/Pacific most of the capex was allocated to projects applying the integrated business model
- Around € 450 m invested in the growth region of Greater China
- In Americas investments were driven by Healthcare and Tonnage



### Mega-trend | Energy/Environment Market estimates 2020 & 2030




Market size [€bn]	2020E	2030E	Assumptions for 2030
Clean Coal & Gas	2-3	15 - 35	<ul> <li>250 projects in commercial phase in 2018 - 2030</li> <li>0.5-0.9 Gt at €30-40 per ton CO<sub>2</sub></li> <li>Incl. industrial CO<sub>2</sub> capture &amp; handling of pipeline CO<sub>2</sub></li> <li>Commercial demonstration until 2018</li> </ul>
LNG	6 - 10	15 - 30	<ul> <li>Use case specific projection of conversion rate for truck, marine, oil &amp; gas industrial and power use of LNG (substitution of liquid fuels like diesel and propane)</li> <li>Not included: Chinese market potentially applicable to internat. players</li> </ul>
EOR/EGR*	4 - 5	12 - 25	<ul> <li>100 CO<sub>2</sub> projects in commercial phase in 2018 – 2030 (also incl. in clean coal &amp; gas)</li> <li>150 N<sub>2</sub> projects in commercial phase in 2018 – 2030</li> <li>Bottom-up planning of projects until 2018</li> </ul>
H <sub>2</sub> fueling	1	5 - 10	<ul> <li>Ramp up of serial fuel cell cars and corresponding H<sub>2</sub>-infrastructure following OEM projections</li> <li>Specific H<sub>2</sub>-consumption around 1kg/100 km, i.e. 100-150kg/year &amp; car</li> </ul>
GTL	1.5 - 2	3.5	<ul> <li>Installation of 4-6 large scale GTL-plants based on cheap available natural gas e.g. from unconventional reserves</li> </ul>
Renewables	1	2	<ul> <li>Includes gases used for manufacturing of photovoltaic cells</li> <li>Biomass gasification and liquefaction</li> </ul>
Range	15 - 20	50 - 100	* Assuming 100% build own operate and excluding sale of equipment and plants

General assumptions:

- Market numbers are directional only and w/o inflation or currency
- Oil price development at 80-100 USD/bll
- Outsourced gases market only (excl. captive market or equipment revenue)

# **Engineering Division | Order intake & backlog** FY 2013 – new record levels






### **Group | BOC PPA** Expected depreciation & amortisation



- Development of depreciation and amortisation
- Impact in 2013: € 225 million
- Expected range adjusted due to exchange rate effects

Expected range [€m]					
2014	215 - 225				
2015	200 - 220				
2022	< 125				



### Expected range [€m]



Operating Profit		
Return		
EBIT		
adjusted for amortisation of intangible		
assets and depreciation of tangible assets		

Return on Capital Employed (ROCE)

Return

**EBIT** 

#### Average Capital Employed

Equity (incl. non-controlling interests)

- + financial debt
- + liabilities from finance leases
- + net pension obligations
- cash, cash equivalents and securities
- receivables from finance leases

Earnings per Share (EPS)

Return

Profit for the period attributable to Linde AG shareholders

Shares

Number of weighted average outstanding shares

### **Investor Relations**



#### Contact

Phone:	+49 89 357 57 1321
Email:	investorrelations@linde.com
Internet:	www.linde.com

### Financial calendar 2014

—	3M report	06 May
—	AGM	20 May
—	6M report	29 July
—	Capital Market Day	13 & 14 October
—	9M report	30 October